BioCentury
ARTICLE | Company News

Ophthotech, Novo A/S deal

June 3, 2013 7:00 AM UTC

Ophthotech granted Novo undisclosed royalties on sales of age-related macular degeneration (AMD) drug Fovista in exchange for $125 million. Ophthotech received $41.7 million in the first tranche and is eligible for two equal, subsequent tranches based on recruitment milestones in a Phase III trial of Fovista expected to start in 3Q13. Fovista is a pegylated aptamer against platelet derived growth factor B ( PDGFB; PDGF2). ...